MKP1-dependent PTH modulation of bone matrix mineralization in female mice is osteoblast maturation stage specific and involves P-ERK and p-p38 MAPKs

Journal of Endocrinology

Volumn 216, Issue 3, 2013, Pages 315-329

  Mahalingam, Chandrika D ^a   Sampathi, Bharat Reddy ^a   Sharma, Sonali ^a   Datta, Tanuka ^a   Das, Varsha ^a   Abou Samra, Abdul B ^a   Datta, Nabanita S ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MAPK; Mineralization; MKP1; Osteoblast; PTH

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; OSTEOCALCIN; PARATHYROID HORMONE;

ANIMAL CELL; ARTICLE; BONE MATURATION; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; FEMALE; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STABLE EXPRESSION; WESTERN BLOTTING;

ANIMALS; BUTADIENES; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; DOWN-REGULATION; DUAL SPECIFICITY PHOSPHATASE 1; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; IMIDAZOLES; MALE; MICE; MICE, KNOCKOUT; NITRILES; OSTEOBLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARATHYROID HORMONE; PHOSPHORYLATION; PYRIDINES;

EID: 84875074800     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0372     Document Type: Article

References (73)

1. Barone LM, Owen TA, Tassinari MS, Bortell R, Stein GS & Lian JB. 1991 Developmental expression and hormonal regulation of the rat matrix Gla protein (MGP) gene in chondrogenesis and osteogenesis. Journal of Cellular Biochemistry 46 351-365.
2. Bienvenu F, Gascan H & Coqueret O. 2001 Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism. Journal of Biological Chemistry 276 16840-16847.
3. Bikle DD & Wang Y. 2012 Insulin like growth factor-I: a critical mediator of the skeletal response to parathyroid hormone. Current Molecular Pharmacology 5 135-142.
4. Callewaert F, Venken K, Kopchick JJ, Torcasio A, van Lenthe GH, Boonen S & Vanderschueren D. 2010 Sexual dimorphism in cortical bone size and strength but not density is determined by independent and timespecific actions of sex steroids and IGF-1: evidence from pubertal mouse models. Journal of Bone and Mineral Research 25 617-626.
5. Cappuzzo KA & Delafuente JC. 2004 Teriparatide for severe osteoporosis. Annals of Pharmacotherapy 38 294-302.
6. Carlson J, Cui W, Zhang Q, Xu X, Mercan F, Bennett AM & Vignery A. 2009 Role of MKP-1 in osteoclasts and bone homeostasis. American Journal of Pathology 175 1564-1573.
7. Chen C, Koh AJ, Datta NS, Zhang J, Keller ET, Xiao G, Franceschi RT, D'Silva NJ & McCauley LK. 2004 Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. Journal of Biological Chemistry 279 29121-29129.
8. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM & Flavell RA. 2006 Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. PNAS 103 2274-2279.
9. Datta NS. 2011 Osteoporotic fracture and parathyroid hormone. World Journal of Orthopedics 2 67-74.
10. Datta NS & Abou-Samra AB. 2009 PTH and PTHrP signaling in osteoblasts. Cellular Signalling 21 1245-1254.
11. Datta NS, Chen C, Berry JE & McCauley LK. 2005 PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. Journal of Bone and Mineral Research 20 1051-1064.
12. Datta NS, Pettway GJ, Chen C, Koh AJ & McCauley LK. 2007 Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. Journal of Bone and Mineral Research 22 951-964.
13. Datta NS, Kolailat R, Fite A, Pettway G & Abou-Samra AB. 2010a Distinct roles for mitogen-activated protein kinase phosphatase-1 (MKP-1) and ERK-MAPK in PTH1R signaling during osteoblast proliferation and differentiation. Cellular Signalling 22 457-466.
14. Datta NS, Samra TA, Mahalingam CD, Datta T & Abou-Samra AB. 2010b Role of PTH1R internalization in osteoblasts and bone mass using a phosphorylation-deficient knock-in mouse model. Journal of Endocrinology 207 355-365.
15. Datta NS, Samra TA & Abou-Samra AB. 2012 Parathyroid hormone (PTH) induces bone formation in phosphorylation deficient PTHR1 knock-in mice. American Journal of Physiology. Endocrinology and Metabolism 302 E1183-E1188.
16. Dominguez LJ, Di Bella G, Belvedere M & Barbagallo M. 2011 Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology 12 397-408.
17. Dong C, Davis RJ & Flavell RA. 2002 MAP kinases in the immune response. Annual Review of Immunology 20 55-72.
18. Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA & Bravo R. 1996 Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 13 925-931.
19. Ebisuya M, Kondoh K & Nishida E. 2005 The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity. Journal of Cell Science 118 2997-3002.
20. Fei Y & Hurley MM. 2012 Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on boneformation. Journal of Cellular Physiology 227 3539-3545.
21. Feng X & McDonald JM. 2011 Disorders of bone remodeling. Annual Review of Pathology 6 121-145.
22. Gladden AB & Diehl JA. 2005 Location, location, location: the role of cyclin D1 nuclear localization in cancer. Journal of Cellular Biochemistry 96 906-913.
23. Gopalakrishnan R, Ouyang H, Somerman MJ, McCauley LK & Franceschi RT. 2001 Matrix gamma-carboxyglutamic acid protein is a key regulator of PTH-mediated inhibition of mineralization in MC3T3-E1 osteoblast-like cells. Endocrinology 142 4379-4388.
24. Gopalakrishnan R, Suttamanatwong S, Carlson AE & Franceschi RT 2005 Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization. Cells, Tissues, Organs 181 166-175.
25. Greenfield EM 2012 Anabolic effects of intermittent PTH on osteoblasts. Current Molecular Pharmacology 5 127-134
26. Hartmann C. 2009 Transcriptional networks controlling skeletal development. Current Opinion in Genetics & Development 19 437-443.
27. Hu Y, Chan E, Wang SX & Li B. 2003 Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation. Endocrinology 144 2068-2074.
28. Inoue K & Sherr CJ. 1998 Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Molecular and Cellular Biology 18 1590-1600.
29. Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, Grumont RJ, Gillieron C, Mackay F, Grey S, Camps M et al. 2006 Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nature Immunology 7 274-283.
30. Kenner L, Hoebertz A, Beil T, Keon N, Karreth F, Eferl R, Scheuch H, Szremska A, AmlingM, Schorpp-KistnerMet al. 2004 Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. Journal of Cell Biology 164 613-623.
31. Khoshniat S, Bourgine A, Julien M, Petit M, Pilet P, Rouillon T, Masson M, Gatius M, Weiss P, Guicheux J et al. 2011 Phosphate-dependent stimulation of MGP and OPN expression in osteoblasts via the ERK1/2 pathway is modulated by calcium. Bone 48 894-902.
32. Khosla S & Riggs BL. 2005 Pathophysiology of age-related bone loss and osteoporosis. Endocrinology and Metabolism Clinics of North America 34 1015-1030, xi.
33. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D & Potts JT. 2012 Benefits and risks of bisphosphonate therapy for osteoporosis. Journal of Clinical Endocrinology and Metabolism 97 2272-2282.
34. Kostenuik PJ, Harris J, Halloran BP, Turner RT, Morey-Holton ER&Bikle DD. 1999 Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I. Journal of Bone and Mineral Research 14 21-31.
35. Kular J, Tickner J, Chim SM & Xu J. 2012 An overview of the regulation of bone remodelling at the cellular level. Clinical Biochemistry 45 863-873.
36. Kyono A, Avishai N, Ouyang Z, Landreth GE & Murakami S. 2012 FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation. Journal of Bone and Mineral Metabolism 30 19-30.
37. Lai LP & Mitchell J. 2009 Parathyroid hormone inhibits phosphorylation of mitogen-activated protein kinase (MAPK) ERK1/2 through inhibition of c-Raf and activation of MKP-1 in osteoblastic cells. Cell Biochemistry and Function 27 269-275.
38. Lamb J, Ladha MH, McMahon C, Sutherland RL & Ewen ME. 2000 Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Molecular and Cellular Biology 20 8667-8675.
39. Lin HM, Zhao L & Cheng SY. 2002 Cyclin D1 is a ligand-independent co-repressor for thyroid hormone receptors. Journal of Biological Chemistry 277 28733-28741.
40. Lombardi G, Di Somma C, Vuolo L, Guerra E, Scarano E & Colao A. 2010 Role of IGF-I on PTH effects on bone. Journal of Endocrinological Investigation 33 22-26.
41. Ma L, Choudhary S, Voznesensky O, Raisz L & Pilbeam C. 2009 Effects of MKP-1 deletion on osteoblast growth and differentiation. In American Society of Bone and Mineral Research (ASBMR), p MO 0186. Denver, CO.
42. Mahalingam CD, Datta T, Patil RV, Kreider J, Bonfil RD, Kirkwood KL, Goldstein SA, Abou-Samra AB & Datta NS. 2011 Mitogen activated protein kinase phosphatase-1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone. Journal of Endocrinology 211 145-156.
43. Manolagas SC. 2000 Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrine Reviews 21 115-137.
44. Marsh ME, Munne AM, Vogel JJ, Cui Y & Franceschi RT. 1995 Mineralization of bone-like extracellular matrix in the absence of functional osteoblasts. Journal of Bone and Mineral Research 10 1635-1643.
45. Marshall CJ. 1995 Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80 179-185.
46. McMahon C, Suthiphongchai T, DiRenzo J & Ewen ME. 1999 P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. PNAS 96 5382-5387.
47. Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, WongM & Marcus R. 2007 Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. Journal of Clinical Endocrinology and Metabolism 92 3535-3541.
48. Musgrove EA. 2006 Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24 13-19.
49. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, Suda T, Yoshiki S & Takahashi HE. 1994 Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiationof osteoprogenitor cells in bone marrow. Bone 15 717-723.
50. Nuedling S, Kahlert S, Loebbert K, Meyer R, Vetter H & Grohe C. 1999 Differential effects of 17b-estradiol on mitogen-activated protein kinase pathways in rat cardiomyocytes. FEBS Letters 454 271-276.
51. Owens DM & Keyse SM. 2007 Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26 3203-3213.
52. Perrini S, Natalicchio A, Laviola L, Cignarelli A, Melchiorre M, De Stefano F, Caccioppoli C, Leonardini A, Martemucci S, Belsanti G et al. 2008 Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology 149 1302-1313.
53. Petre CE, Wetherill YB, Danielsen M & Knudsen KE. 2002 Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. Journal of Biological Chemistry 277 2207-2215.
54. Piechaczyk M & Farras R. 2008 Regulation and function of JunB in cell proliferation. Biochemical Society Transactions 36 864-867.
55. Qin L, Raggatt LJ & Partridge NC. 2004 Parathyroid hormone: a doubleedged sword for bone metabolism. Trends in Endocrinology and Metabolism 15 60-65.
56. Raisz LG. 2005 Pathogenesis of osteoporosis: concepts, conflicts, and prospects. Journal of Clinical Investigation 115 3318-3325.
57. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ & Pestell RG. 2001 Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBPassociated factor (P/CAF)-dependent manner. Molecular Endocrinology 15 797-811.
58. Rey A, Manen D, Rizzoli R, Ferrari SL & Caverzasio J. 2007 Evidences for a role of p38 MAP kinase in the stimulation of alkaline phosphatase and matrix mineralization induced by parathyroid hormone in osteoblastic cells. Bone 41 59-67.
59. Sherr CJ & Roberts JM. 2004 Living with or without cyclins and cyclindependent kinases. Genes and Development 18 2699-2711.
60. Silva BC, Costa AG, Cusano NE, Kousteni S & Bilezikian JP. 2011 Catabolic and anabolic actions of parathyroid hormone on the skeleton. Journal of Endocrinological Investigation 34 801-810.
61. Stein GS & Lian JB. 1993 Molecular mechanisms mediating developmental and hormone-regulated expression of genes in osteoblasts: an integrated relationship of cell growth and differentiation. In Cellular and Molecular Biology of Bone, pp 47-95. Ed M Noda. Tokyo: Academic Press.
62. Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S & Marumo F. 1999 Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade. Kidney International 56 1258-1261.
63. Thouverey C & Caverzasio J. 2012 The p38alpha MAPK positively regulates osteoblast function and postnatal bone acquisition. Cellular and Molecular Life Sciences 69 3115-3125.
64. Tilmann C & Kimble J. 2005 Cyclin D regulation of a sexually dimorphic asymmetric cell division. Developmental Cell 9 489-499.
65. Vilatoba M, Eckstein C, Bilbao G, Frennete L, Eckhoff DE & Contreras JL. 2005 17b-Estradiol differentially activates mitogen-activated proteinkinases and improves survival following reperfusion injury of reducedsize liver in mice. Transplantation Proceedings 37 399-403.
66. Wada T & Penninger JM. 2004 Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23 2838-2849.
67. Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD & Franceschi RT. 2002 Bone morphogenetic proteins, extracellular matrix, and mitogenactivated protein kinase signaling pathways are required for osteoblastspecific gene expression and differentiation in MC3T3-E1 cells. Journal of Bone and Mineral Research 17 101-110.
68. Yu EW, Kumbhani R, Siwila-Sackman E & Leder BZ. 2011 Acute decline in serum sclerostin in response to PTH infusion in healthy men. Journal of Clinical Endocrinology and Metabolism 96 E1848-E1851.
69. Zhang L, Li B, Zhao W, Chang YH, Ma W, Dragan M, Barker JL, Hu Q & Rubinow DR. 2002 Sex-related differences in MAPKs activation in rat astrocytes: effects of estrogen on cell death. Brain Research. Molecular Brain Research 103 1-11.
70. Zhang Y, Blattman JN, Kennedy NJ, Duong J, Nguyen T, Wang Y, Davis RJ, Greenberg PD, Flavell RA & Dong C. 2004 Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 430 793-797.
71. Zhang Q, Muller M, Chen CH, Zeng L, Farooq A & Zhou MM. 2005 New insights into the catalytic activation of the MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding. Journal of Molecular Biology 354 777-788.
72. Zhang MY, Ranch D, Pereira RC, Armbrecht HJ, Portale AA & Perwad F. 2012 Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology 153 1806-1816.
73. Zhao Q, Shepherd EG, Manson ME, Nelin LD, Sorokin A & Liu Y. 2005 The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. Journal of Biological Chemistry 280 8101-8108.